Pragmatic clinical trials: Emerging challenges and new roles for statisticians

Clinical Trials

Volumn 13, Issue 5, 2016, Pages 471-477

  Califf, Robert M ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Biostatistics; clinical trial; electronic health record; evidence; pragmatic clinical trial; quality by design; randomization; statistics

Indexed keywords

ARTICLE; BIOSTATISTICS; CLINICAL RESEARCH; COMMUNICATION SKILL; DATA ANALYSIS; EDUCATION PROGRAM; ELECTRONIC HEALTH RECORD; HUMAN; INFORMATION PROCESSING; PEER REVIEW; PRIORITY JOURNAL; QUALITY BY DESIGN; QUANTITATIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELIABILITY; RESEARCH PRIORITY; STUDY DESIGN; VALIDITY; CLINICAL TRIAL (TOPIC); MEDICAL RESEARCH; PROCEDURES; REPRODUCIBILITY; STATISTICS;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DATA COLLECTION; ELECTRONIC HEALTH RECORDS; HUMANS; REPRODUCIBILITY OF RESULTS; STATISTICS AS TOPIC;

EID: 84987707866     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774516656944     Document Type: Article

References (41)

1. Zelen M,. Biostatisticians, biostatistical science and the future. Stat Med 2006; 25: 3409-3414.
2. Open Science Collaboration. Estimating the reproducibility of psychological science. Science 2015; 349: aac4716.
3. Ioannidis JP,. Why most published research findings are false. PLoS Med 2005; 2: e124.
4. Le Noury J, Nardo JM, Healy D, et al. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ 2015; 351: h4320.
5. Clinical Trials Transformation Initiative. QBD (Quality by Design) Toolkit., http://www.ctti-clinicaltrials.org/toolkit/qbd (. accessed 2 October 2015).
6. Hill AB,. Medical ethics and controlled trials. Br Med J 1963; 1: 1043-1049.
7. Robert Wood Johnson Foundation. Culture of health. Commission to build a healthier America's city maps show dramatic differences in life expectancy, http://www.rwjf.org/en/culture-of-health/2013/07/commission-to-build.html (2013,. accessed 2 October 2015).
8. Social Progress Imperative. Social Progress Index. 2015, http://www.socialprogressimperative.org/data/spi (. accessed 2 October 2015).
9. Peterson ED, Roe MT, Mulgund J, et al. Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA 2006; 295: 1912-1920.
10. Tricoci P, Allen JM, Kramer JM, et al. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA 2009; 301: 831-841.
11. Han H, Chao H, Guerra A, et al. Evolution of the American College of Cardiology/American Heart Association Clinical Guidelines. J Am Coll Cardiol 2015; 65: 2726-2734.
12. Precision Medicine Initiative, https://www.whitehouse.gov/precision-medicine (. accessed 22 March 2016).
13. Kim ESH, Carrigan TP, Menon V,. International participation in cardiovascular randomized controlled trials sponsored by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2011; 58: 671-676.
14. Eapen ZJ, Vavalle JP, Granger CB, et al. Rescuing clinical trials in the United States and beyond: a call for action. Am Heart J 2013; 165: 837-847.
15. Berndt ER, Cockburn IM,. Price indexes for clinical trial research: a feasibility study. Monthly Labor Review, 2014, Bureau of Labor Statistics, US Department of Labor, http://www.bls.gov/opub/mlr/2014/article/price-indexes-for-clinical-trial-research-a-feasibility-study-1.htm (2014,. accessed 29 December 2015).
16. Tufts Center for the Study of Drug Development. Cost to develop and win marketing approval for a new drug is $2.6 billion., http://csdd.tufts.edu/news/complete-story/pr-tufts-csdd-2014-cost-study (2014,. accessed 23 November 2015).
17. Reardon S,. Regulators adopt more orphan drugs. Nature 2014; 508: 16-17.
18. Schwartz D, Lellouch J,. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis 1967; 20: 637-648.
19. Tunis SR, Stryer DB, Clancy CM,. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003; 290: 1624-1632.
20. Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol 2009; 62: 464-475.
21. Califf RM, Sugarman J,. Exploring the ethical and regulatory issues in pragmatic clinical trials. Clin Trials 2015; 12: 436-441.
22. US Food and Drug Administration. E6 good clinical practice: consolidated guidance for industry. ICH, 1996, http://www.fda.gov/downloads/Drugs/./Guidances/ucm073122.pdf (1996,. accessed 11 November 2015).
23. Olsen LA, Aisner D, McGinnis JM, Institute of Medicine. The learning healthcare system. Washington, DC: National Academies Press, 2007.
24. Yusuf S, Collins R, Peto R,. Why do we need some large, simple randomized trials? Stat Med 1984; 3: 409-422.
25. Califf RM, Zarin DA, Kramer JM, et al. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. JAMA 2012; 307: 1838-1847.
26. Lauer MS, Danthi NS, Kaltman J, et al. Predicting productivity returns on investment: thirty years of peer review, grant funding, and publication of highly cited papers at the National Heart, Lung, and Blood Institute. Circ Res 2015; 117: 239-243.
27. Anderson ML, Chiswell K, Peterson ED, et al. Compliance with results reporting at ClinicalTrials.gov. N Engl J Med 2015; 372: 1031-1039.
28. Hunter NL, Califf RM,. FDA Voice. FDA announces first-ever Patient Engagement Advisory Commission., http://blogs.fda.gov/fdavoice/index.php/2015/09/fda-announces-first-ever-patient-engagement-advisory-committee/ (2015,. accessed 2 October 2015).
29. Hunter NL, O'Callghan K, Califf RM,. Engaging patients across the spectrum of medical product development: view from the US Food and Drug Administration. JAMA 2015; 314: 2499-2500.
30. Patient-Centered Clinical Research Network (PCORnet). PCORnet Patient Council., http://pcornet.org/about-pcornet/pcornet-patient-council/ (. accessed 2 October 2015).
31. Willan AR, Pinto EM,. The value of information and optimal clinical trial design. Stat Med 2005; 24: 1791-1806.
32. Davenport TH,. How to design smart business experiments. Harvard Business Review, 2009, https://hbr.org/2009/02/how-to-design-smart-business-experiments (2009,. accessed 2 October 2015).
33. Ellenberg SS, Culbertson R, Gillen DL, et al. Data monitoring committees for pragmatic clinical trials. Clin Trials 2015; 12: 530-536.
34. Rethinking clinical trials: a living textbook of pragmatic clinical trials. Tools for research. Biostatistical guidance document: The intraclass correlation coefficient, https://www.nihcollaboratory.org/Products/Intraclass-correlation-coeffecient-V1.0.pdf (. accessed 2 October 2015).
35. National Patient-Centered Clinical Research Network (PCORnet) website. Governance policies for PCORnet, the National Patient-Centered Clinical Research Network., http://www.pcornet.org/wp-content/uploads/2016/02/PCORnet-Governance-Policy-Februay-2016-edited.pdf (. accessed 9 May 2016).
36. Killen J, Harrington M, Fauci AS,. MSM, AIDS research activism, and HAART. Lancet 2012; 380: 314-316.
37. Chen R, Desai NR, Ross JS, et al. Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers. BMJ 2016; 352: i637.
38. Califf RM, Kornbluth S,. Establishing a framework for improving the quality of clinical and translational research. J Clin Oncol 2012; 30: 1725-1726.
39. National Institutes of Health. Data and Informatics Working Group-Draft Report to the Advisory Committee to the Director., http://acd.od.nih.gov/Data%20and%20Informatics%20Working%20Group%20Report.pdf (2012,. accessed 22 March 2015).
40. American Statistical Association News. More students earning statistics degrees, but not enough to meet surging demand for statisticians., https://www.sciencedaily.com/releases/2015/10/151001125945.htm (2015,. accessed 23 March 2016).
41. Clinical and Translational Science Awards website. About the CTSA Consortium., https://ctsacentral.org/about-us/ctsa/ (. accessed 23 November 2015).